Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis — Stella

Recruiting

Back to AL Amyloidosis trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(2 sites)

China

Peking University Peoples Hospital, Beijing, Beijing Municipality

Fuxing Hospital affiliated to Capital Medical University, Beijing

Key details

Sponsor

Peking University People's Hospital

Enrollment target

~20 participants

Started

March 2025

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov